Maintenance Notice (10:30 PM August 23 - 3:30 AM August 24, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Product Document Searching Made Easy by 2D Code! | TCI Life Science News August 2025 | [Product Highlights] Puberulic Acid: A Compound with... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
请选择数量
CAS RN: 135062-02-1 | 产品编码: R0179
Repaglinide
×
![]()
×
技术规格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 131.0 to 135.0 °C |
| Specific rotation [a]20/D | +7.0 to +10.0 deg(C=1,MeOH) |
物性（参考值）
| 熔点 | 133 °C |
| 比旋光度 [α]D | 9° (C=1,MeOH) |
GHS
| 象形图 |
|
| 信号词 | Warning |
| 危险性说明 | H302 : Harmful if swallowed. H361 : Suspected of damaging fertility or the unborn child. H362 : May cause harm to breast-fed children. |
| 防范说明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P263 : Avoid contact during pregnancy/ while nursing. P260 : Do not breathe dusts or mists. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
相关法规
| RTECS# | DI0876305 |
运输信息
| HS编码* | 2933.39-000 |
应用
Repaglinide: A Fast-Acting Insulin-Releasing Agent
Repaglinide, a carbamoylmethyl benzoic acid derivative, is a fast-acting insulin-releasing agent. Its mechanism of action is partly similar to that of the sulfonylureas such as glibenclamide [G0382] which binds to the sulfonylurea binding sites on pancreatic β-cells resulting in reducing blood glucose. For details, repaglinide stimulates the release of insulin from pancreatic β-cells by closing ATP-sensitive potassium channels, which results in the opening of calcium channels in the β-cells. Repaglinide is metabolized by CYP2C8 and CYP3A4 enzymes. Repaglinide is used for the treatment of type 2 diabetes. For your reference, [E0928] is a synthetic intermediate of repaglinide. (The product is for research purpose only.)
References
- Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes
- Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus (a review)
- Repaglinide: A review of its therapeutic use in type 2 diabetes mellitus
- Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of fibrates and rifampicin
- Ionization, lipophilicity and solubility properties of repaglinide
- Determination of repaglinide in pharmaceutical formulations by HPLC with UV detection
参考文献
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。